Patents by Inventor Howard Malcolm Prentice

Howard Malcolm Prentice has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10945986
    Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: March 16, 2021
    Assignee: CHS Pharma, Inc.
    Inventors: Jang-Yen Wu, Howard Malcolm Prentice
  • Patent number: 10792260
    Abstract: A method of preventing degeneration of photoreceptor cells in an eye of a mammalian subject includes the step of administering pharmaceutical composition comprising a sulindac agent to the eye of the subject.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: October 6, 2020
    Assignee: CHS PHARMA, INC.
    Inventors: Janet C. Blanks, Howard Malcolm Prentice, Herbert Weissbach
  • Publication number: 20190209512
    Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.
    Type: Application
    Filed: March 18, 2019
    Publication date: July 11, 2019
    Inventors: Jang-Yen Wu, Howard Malcolm Prentice
  • Patent number: 10272063
    Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: April 30, 2019
    Assignee: CHS Pharma, Inc.
    Inventors: Jang-Yen Wu, Howard Malcolm Prentice
  • Publication number: 20180055809
    Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.
    Type: Application
    Filed: November 3, 2017
    Publication date: March 1, 2018
    Inventors: Jang-Yen Wu, Howard Malcolm Prentice
  • Patent number: 9827220
    Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: November 28, 2017
    Assignee: CHS Pharma, Inc.
    Inventors: Jang-Yen Wu, Howard Malcolm Prentice
  • Publication number: 20160074350
    Abstract: A method of preventing degeneration of photoreceptor cells in an eye of a mammalian subject includes the step of administering pharmaceutical composition comprising a sulindac agent to the eye of the subject.
    Type: Application
    Filed: September 22, 2015
    Publication date: March 17, 2016
    Inventors: Janet C. Blanks, Howard Malcolm Prentice, Herbert Weissbach
  • Publication number: 20150265569
    Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.
    Type: Application
    Filed: June 5, 2015
    Publication date: September 24, 2015
    Inventors: Jang-Yen Wu, Howard Malcolm Prentice
  • Patent number: 9050305
    Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: June 9, 2015
    Assignee: CHS Pharma, Inc.
    Inventors: Jang-Yen Wu, Howard Malcolm Prentice
  • Publication number: 20130259824
    Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.
    Type: Application
    Filed: March 29, 2013
    Publication date: October 3, 2013
    Inventors: Jang-Yen Wu, Howard Malcolm Prentice